ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial

Rhea-AI Summary

ADC Therapeutics (NYSE: ADCT) has announced a conference call and webcast scheduled for December 11, 2024, at 8:30 a.m. EST. The company will present preliminary data from the LOTIS-7 Phase 1b clinical trial, which evaluates ZYNLONTA® in combination with bispecific antibody glofitamab (COLUMVI™) for treating relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).

The conference call will be accessible via toll-free dial-in for North America and Canada participants, and a webcast will be available on the company's investor relations website for 30 days following the presentation.

News Market Reaction – ADCT

+63.02%

1 alert

+63.02% News Effect

On the day this news was published, ADCT gained 63.02%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Company to host corporate update webcast to share results on December 11, 2024

LAUSANNE, Switzerland, Dec. 6, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), today announced that it will host a conference call and live webcast on Wednesday, December 11, 2024, at 8:30 a.m. EST to provide an update on preliminary data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA^® in combination with the bispecific antibody glofitamab (COLUMVI^™) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).

To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com. The archived webcast will be available for 30 days following the call.

About ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland, and has operations in London and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on LinkedIn.

ZYNLONTA^® is a registered trademark of ADC Therapeutics SA.

CONTACTS:

Investors
Marcy Graham
ADC Therapeutics
Marcy.Graham@adctherapeutics.com
+1 650-667-6450

Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040

View original content to download multimedia:https://www.prnewswire.com/news-releases/adc-therapeutics-to-provide-initial-data-update-on-lotis-7-clinical-trial-302324496.html

SOURCE ADC Therapeutics SA

FAQ

What is the purpose of ADC Therapeutics' LOTIS-7 Phase 1b trial?

The LOTIS-7 Phase 1b trial evaluates the safety and efficacy of ZYNLONTA® combined with glofitamab (COLUMVI™) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).

When will ADCT present the LOTIS-7 trial preliminary data?

ADC Therapeutics will present the preliminary LOTIS-7 trial data during a conference call and webcast on December 11, 2024, at 8:30 a.m. EST.

How can investors access ADCT's LOTIS-7 data presentation?

Investors can access the presentation through a toll-free dial-in (1-800-836-8184 for North America and Canada) or via webcast on ADC Therapeutics' investor relations website at ir.adctherapeutics.com.